Marshall Wace’s GT Biopharma GTBP Stock Holding History

Marshall Wace’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-553	Closed	-$112K	–	4020
2021 Q3	$112K	Sell	553 -307	-36%	-$92.4K	﹤0.01%	2878
2021 Q2	$400K	Buy	+860	New	+$357K	﹤0.01%	2232

Other funds holding GTBP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Marshall Wace's GTBP Position: Q4 2021 in Review

Marshall Wace sold out of GT Biopharma (GTBP) in Q4 2021, closing a stake of 553 shares — an estimated $112K sold.

Marshall Wace first reported a position in GTBP in Q2 2021 and held it in 2 quarters. The position peaked at $400K in Q2 2021. 53 funds tracked by Wall St. Rank hold GTBP as of Q4 2021.

Marshall Wace reported no remaining GT Biopharma position as of Q4 2021 after selling out during the quarter.
Marshall Wace sold 553 GT Biopharma shares in Q4 2021, an estimated $112K.
Marshall Wace first reported a position in GT Biopharma in Q2 2021 and held it in 2 quarters.
Marshall Wace's GT Biopharma position peaked at $400K in Q2 2021.
53 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2021.

Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.